Interaction of cutaneous lymphoma cells with reactive T cells and dendritic cells: Implications for dendritic cell-based immunotherapy

British Journal of Dermatology

Volumn 149, Issue 6, 2003, Pages 1128-1142

  Thumann, P ^a   Luftl M ^a   Moc, I ^a   Bagot, M ^b   Bensussan, A ^b   Schuler, G ^a   Jenne, L ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b INSERM   (France)

Author keywords

Cutaneous T cell lymphoma; Dendritic cells; Immunotherapy; Regulatory T cells; Vaccination

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL DIVISION; CELL FUNCTION; CELL INTERACTION; CELL LINE; CELL MATURATION; CELL PROLIFERATION; CELL VIABILITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CRYOPRESERVATION; CUTANEOUS T CELL LYMPHOMA; CYTOTOXICITY; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOMA CELL; METHODOLOGY; NECROSIS; PATHOLOGY; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; UPREGULATION;

APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL DIVISION; CELL LINE; CRYOPRESERVATION; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOMA, T-CELL, CUTANEOUS; NECROSIS; PHAGOCYTOSIS; T-LYMPHOCYTES;

EID: 0347356320     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2003.05674.x     Document Type: Article

References (62)

1. Weinstock MA, Horm JW. Mycosis fungoldes in the United States. Increasing incidence and descriptive epidemiology. JAMA 1988; 260: 42-6.
2. Kim YH, Chow S, Varghese A et al. Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides. Arch Dermatol 1999; 135: 26-32.
3. Wood GS, Edinger A, Hoppe RT et al. Mycosis fungoides skin lesions contain CD8+ tumor-infiltrating lymphocytes expressing an activated, MHC restricted cytotoxic T-lymphocyte phenotype. J Cutan Pathol 1994; 21: 151-6.
4. Bagot M, Echchakir H, Mami-Chouaib F et al. Isolation of tumor-specific cytotoxic CD4+ and CD4+ CD8dim+ T-cell clones infiltrating a cutaneous T-cell lymphoma. Blood 1998; 91: 4331-41.
5. Luftl M, Feng A, Schuler G. Dendritic cells and apoptosis in mycosis fungoides. Br J Dermatol 2002; 147: 1171-9.
6. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-52.
7. Banchereau J, Schuler-Thurner B, Palucka AK et al. Dendritic cells as vectors for therapy. Cell 2001; 106: 271-4.
8. Jimbow K, Chiba M, Horikoshi T. Electron microscopic identification of Langerhans cells in the dermal infiltrates of mycosis fungoides. J Invest Dermatol 1982; 78: 102-7.
9. Berger CL, Hanlon D, Kanada D et al. The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells. Blood 2002; 99: 2929-39.
10. Edelson RL. Cutaneous T cell lymphoma: the helping hand of dendritic cells. Ann NY Acad Sci 2001; 941: 1-11.
11. Revy P, Sospedra M, Barbour B et al. Functional antigen-independent synapses formed between T cells and dendritic cells. Nat Immunol 2001; 2: 925-31.
12. Berger CL, Xu AL, Hanlon D et al. Induction of human tumor-loaded dendritic cells. Int J Cancer 2001; 91: 438-47.
13. Berger CL, Wang N, Christensen I et al. The immune response to class I-associated tumor-specific cutaneous T-cell lymphoma antigens. J Invest Dermatol 1996; 107: 392-7.
14. Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annu Rev Immunol 2000; 18: 245-73.
15. Jenne L, Bhardwaj N, Perspectives of DC based immunotherapies. In: Principles and Practice of Oncology (DeVita VT, Hellman S, Rosenberg SA, eds). 6th edn, Vol. 15. Philadelphia: Lippincott. Williams & Wilkins, 2001: 1-15.
16. Haffner AC, Tassis A, Zepter K et al. Expression of cancer/testis antigens in cutaneous T cell lymphomas. Int J Cancer 2002; 97: 668-70.
17. Whiteside TL. Signaling defects in T lymphocytes of patients with malignancy. Cancer Immunol Immunother 1999; 48: 346-52.
18. Lee PP, Yee C, Savage PA et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999; 5: 677-85.
19. Ni X, Hazarika P, Zhang C et al. Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape? Clin Cancer Res 2001; 7: 2682-92.
20. Asadullah K, Docke WD, Haeussler A et al. Progression of mycosis fungoides is associated with increasing cutaneous expression of interleukin-10 mRNA. J Invest Dermatol 1996; 107: 833-7.
21. Poszepczynska E, Bagot M, Echchakir H et al. Functional characterization of an IL-7-dependent CD4(+) CD8alphaalpha(+) Th3-type malignant cell line derived from a patient with a cutaneous T-cell lymphoma. Blood 2000; 96: 1056-63.
22. Dieckmann D, Plottner H, Berchtold S et al. Ex vivo isolation and characterization of CD4(+) CD25(+) T cells with regulatory properties from human blood. J Exp Med 2001; 193: 1303-10.
23. Jonuleit H, Schmitt E, Stassen M et al. Identification and functional characterization of human CD4(+) CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med 2001; 193: 1285-94.
24. Read S, Powrie F. CD4(+) regulatory T cells. Curr Opin Immunol 2001; 13: 644-9.
25. Guermonprez P, Valladeau J, Zitvogel L et al. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 2002; 20: 621-67.
26. Jonuleit H, Schmitt E, Schuler G et al. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000; 192: 1213-22.
27. Herr W, Ranieri E, Olson W et al. Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD8(+) T lymphocyte responses. Blood 2000; 96: 1857-64.
28. Glaser A, Schuler-Thurner B, Feuerstein B et al. Collection of MNCs with two cell separators for adoptive immunotherapy in patients with stage IV melanoma. Transfusion 2001; 41: 117-22.
29. Jonuleit H, Kuhn U, Muller G et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997; 27: 3135-42.
30. Albert ML, Pearce SF, Francisco LM et al. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med 1998; 188: 1359-68.
31. Feuerstein B, Berger TG, Maczek C et al. A method for the production of cryopreserved aliquots of antigen-preloaded, mature dendritic cells ready for clinical use. J Immunol Methods 2000; 245: 15-29.
32. Lutz M, Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol 2002; 23: 445-9.
33. Marolleau JP, Baccard M, Flageul B et al. High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma. Arch Dermatol 1995; 131: 574-9.
34. Rook AH, Wood GS, Yoo EK et al. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 1999; 94: 902-8.
35. Gellrich S, Lukowsky A, Schilling T et al. Microanatomical compartments of clonal and reactive T cells in mycosis fungoides: molecular demonstration by single cell polymerase chain reaction of T cell receptor gene rearrangements. J Invest Dermatol 2000; 115: 620-4.
36. Hoppe RT, Medeiros LJ, Warnke RA et al. CD8-positive tumor-infiltrating lymphocytes influence the long-term survival of patients with mycosis fungoides. J Am Acad Dermatol 1995; 32: 448-53.
37. Bagot M, Nikolova M, Schirm-Chabanette F et al. Crosstalk between tumor T lymphocytes and reactive T lymphocytes in cutaneous T cell lymphomas. Ann NY Acad Sci 2001; 941: 31-8.
38. Levings MK, Sangregorio R, Roncarolo MG. Human CD25(+) CD4(+) T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med 2001; 193: 1295-302.
39. Wood NL, Kitces EN, Blaylock WK. Depressed lymphokine activated killer cell activity in mycosis fungoides. A possible marker for aggressive disease. Arch Dermatol 1990; 126: 907-13.
40. Asadullah K, Friedrich M, Docke WD et al. Enhanced expression of T-cell activation and natural killer cell antigens indicates systemic anti-tumor response in early primary cutaneous T-cell lymphoma. J Invest Dermatol 1997; 108: 743-7.
41. Sotomayor EM, Borrello I, Rattis FM et al. Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression. Blood 2001; 98: 1070-7.
42. Yoo EK, Rook AH, Elenitsas R et al. Apoptosis induction of ultraviolet light A and photochemotherapy in cutaneous T-cell lymphoma: relevance to mechanism of therapeutic action. J Invest Dermatol 1996; 107: 235-42.
43. Meissner K, Loning T, Rehpenning W. Epidermal Langerhans cells and prognosis of patients with mycosis fungoides and Sézary syndrome. In Vivo 1993; 7: 277-80.
44. Rook AH, Suchin KR, Kao DM et al. Photopheresis: clinical applications and mechanism of action. J Invest Dermatol Symp Proc 1999; 4: 85-90.
45. Amoscato AA, Prenovitz DA, Lotze MT. Rapid extracellular degradation of synthetic class I peptides by human dendritic cells. J Immunol 1998; 161: 4023-32.
46. Jenne L, Arrighi JF, Jonuleit H et al. Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis. Cancer Res 2000; 60: 4446-52.
47. Berger CL, Longley J, Hanlon D et al. The clonotypic T cell receptor is a source of tumor-associated antigens in cutaneous T cell lymphoma. Ann NY Acad Sci 2001; 941: 106-22.
48. Lim SH, Bailey-Wood R. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma. Int J Cancer 1999; 83: 215-22.
49. Reichardt VL, Okada CY, Liso A et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - a feasibility study. Blood 1999; 93: 2411-19.
50. Hsu FJ, Benike C, Fagnoni F et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996; 2: 52-8.
51. Li G, Chooback L, Wolfe JT et al. Overexpression of p53 protein in cutaneous T cell lymphoma: relationship to large cell transformation and disease progression. J Invest Dermatol 1998; 110: 767-70.
52. Eichmuller S, Usener D, Dummer R et al. Serological detection of cutaneous T-cell lymphoma-associated antigens. Proc Natl Acad Sci USA 2001; 98: 629-34.
53. Linnemann T, Tumenjargal S, Gellrich S et al. Mimotopes for tumor-specific T lymphocytes in human cancer determined with combinatorial peptide libraries. Eur J Immunol 2001; 31: 156-65.
54. Thumann P, Moc I, Humrich J et al. Antigen loading of dendritic cells with whole tumor cell preparations. J Immunol Methods 2003; 277: 1-16.
55. Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4: 328-32.
56. Larsson M, Fonteneau JF, Bhardwaj N. Dendritic cells resurrect antigens from dead cells. Trends Immunol 2001; 22: 141-8.
57. Jenne L, Sauter B. Dendritic cells pulsed with apoptotic tumor cells as vaccine. In: Apoptosis and Autoimmunity (Kalden JR, Herrmann M, eds). Chichester: Wiley, 2002; 208-26.
58. Li M, Davey GM, Sutherland RM et al. Cell-associated ovalbumin is cross-presented much more efficiently than soluble ovalbumin in vivo. J Immunol 2001; 166: 6099-103.
59. Schnurr M, Scholz C, Rothenfusser S et al. Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gamma delta T cells. Cancer Res 2002; 62: 2347-52.
60. Galea-Lauri J, Darling D, Mufti G et al. Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination. Cancer Immunol Immunother 2002; 51: 299-310.
61. Sauter B, Albert ML, Francisco L et al. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 2000; 191: 423-34.
62. Heald P, Yan SL, Edelson R. Profound deficiency in normal circulating T cells in erythrodermic cutaneous T-cell lymphoma. Arch Dermatol 1994; 130: 198-203.